Zdrowie i gospodarka · 11/12/2014
FDA Releases Draft Guidance on Bioequivalence Recommendations for Budesonide Extended-Release Tablets
The FDA has made available a draft guidance document outlining specific recommendations for bioequivalence studies to support the approval of budesonide extended-release tablets through abbreviated new drug applications (ANDAs)